Application and progression of ablation combined with targeted therapies in the treatment of liver cancer

Abstract

Abstract: Liver cancer is one of the most common malignant tumors worldwide.Furthermore,China has the world's highest incidence rate and the largest number of deaths.At present,the most commonly used radical treatment for liver cancer is surgical resection and local ablation.However,due to its insidious onset,rapid progression,early recurrence and poor prognosis,many patients have reached advanced stage when diagnosed.In recent years,with the application of targeted drugs,the curative effect of liver cancer patients has been significantly improved.This article will review the effect of ablation combined with targeted therapy for liver cancer.

Key words: Liver cancer, Ablation therapies, Targeted therapies

Yan Xue, Han Yue. Application and progression of ablation combined with targeted therapies in the treatment of liver cancer[J]. Electronic Journal of Liver Tumor, 2020, 7(3): 36-38.

References

[1] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al.Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8):1941-1953.
[2] 全国肝癌合并癌栓诊治研究协作组. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版)[J]. 肝癌电子杂志, 2018, 5(2):1-7.
[3] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019 年版)[J]. 肝癌电子杂志 , 2020, 7(1):5-23.
[4] 郑加生. 中国肝癌消融治疗现状与未来[J]. 肝癌电子杂志, 2015, 2(2):1-4.
[5] 李晓光. 肝癌消融联合靶向药物治疗[J].肝癌电子杂志, 2017, 4(4):21-26.
[6] DENG GL, ZENG S, SHEN H.Chemotherapy and target therapy for hepatocellular carcinoma:New advances and challenges[J]. World J Hepatol, 2015, 7(5):787-798.
[7] CHEN L, MA XM, LIU X, et al.Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma:a systematic review and meta-analysis[J]. J BUON, 2017, 22(6):1525-1532.
[8] YAN S, ZHANG Y, SUN C, et al.The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma[J]. Oncol Lett, 2016, 12(2):951-955.
[9] XIA Y, LI J, LIU GH, et al.Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma:A Randomized Clinical Trial[J]. JAMA Oncol,2019, 6(2):255-263.
[10] YI P, ZHANG M, ZHAO J, et al.Liver resection for intermediate hepatocellular carcinoma[J]. World J Hepatol ,2016,8(14):607-615.
[11] BRUIX J, TAKAYAMA T, MAZZAFERRO V, et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM):a phase 3, randomised, double-blind, placebocontrolled trial[J]. Lancet Oncol, 2015, 16(13):1344-1354.
[12] PISCAGLIA F, GIANSTEFANI A, RAVAIOLI M, et al.Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation[J]. Liver Transpl,2010, 16(5):658-667.
[13] SHAO YY, SHAU WY, CHAN SY, et al.Treatment efficacy diffe-rences of sorafenib for advanced hepatocellular carcinoma:a meta-analysis of randomized clinical trials[J]. Oncology, 2015, 88(6):345-352.
[14] CHENG SQ, CHEN MS, CAI JQ, et al.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition[J]. Oncotarget, 2017, 8(5):8867-8876.
[15] CERRITO L, ELEONORA ANNICCHIARICO, IEZZI R, et al.Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis:Beyond the known frontiers[J]. World J Gastroenterol, 2019, 25(31):4360-4382.
[16] BRUIX J, RAOUL J, SHERMAN M, et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J]. J Hepatol, 2012, 57(4):821-829.
[17] CHENG A, GUAN ZZ, CHEN ZD, et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III Sorafenib Asia-Pacific trial[J]. Eur J Cancer, 2012, 48(10):1452-1465.
[18] GIORGIO A, GABRIELLA MEROLA M, MONTESARCHIO L, et al.Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein:a western randomized controlled trial[J]. Anticancer Res, 2016, 36(11):6179-6183.
[19] R SMOLOCK A, M CRISTESCU M, HINSHAW A, et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3-to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone[J]. Abdom Radiol(NY), 2018, 43(9):2497-2504.
[20] HU H, CHEN GF, YUAN W, et al.Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8):1351-1358.
[21] XU LF, SUN HL, CHEN YT, et al.Large primary hepatocellular carcinoma: transarterialchemoembolization monotherapy versus combined transarterialchemoembolization percutaneous microwave coagulationtherapy[J]. J Gastroenterol Hepatol, 2013, 28:456-463.
[22] PENG ZW, CHEN SL, WEI MC, et al.Advanced Recurrent Hepatocellular Carcinoma:Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation[J]. Radiology, 2018, 287(2):705-714.
[23] NI JY, SUN HL, LUO JH, et al.Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma:A Preliminary Investigation of Safety and Efficacy[J]. Cancer Manag Res, 2019, 11:9939-9950.
[24] QI XS, GUO XZ.Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis:a systematic review of comparative studies, Prz Gastroenterol, 2015, 10(3):142-147.
[25] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[26] PINYOL R, MONTAL R, BASSAGANYAS L, et al.Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial[J]. Gut, 2019, 68(6):1065-1075.
[27] TANG Z, KANG MX, ZHANG B, et al.Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma[J].Tumori,2017, 103(3):286-291.
[28] DE MATTIA E, CECCHIN E, GUARDASCIONE M, et al.Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma[J]. World J Gastroenterol,2019, 25(29):3870-3896.
[29] BRUIX J, QIN SK, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet,2017, 389(10064):56-66.
[30] KUDO M, S FINN R, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
[31] IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol,2017, 52(4):512-519.